Form 4: Integra LifeSciences Executive Disposes of Shares for Tax Obligations
Insider Transaction Report
Jeffrey Mosebrook, SVP, Fin & Princ Acct Officer at Integra LifeSciences Holdings Corp, disposed of 3,345 shares of common stock to cover tax withholding obligations.
Summary
- Jeffrey Mosebrook, the Senior Vice President, Finance & Principal Accounting Officer of Integra LifeSciences Holdings Corp (IART), reported a transaction.
- On July 3, 2025, Mr. Mosebrook disposed of 3,345 shares of common stock.
- The disposition was made at a price of $13.49 per share.
- The transaction was coded 'F', indicating a disposition to the issuer to satisfy tax withholding obligations.
- Following this transaction, Mr. Mosebrook beneficially owns 36,600 shares of common stock directly.
- The transaction was executed pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 5
Explanation: The transaction is a routine disposition of shares to cover tax withholding obligations, which is a common and expected event for executives receiving equity compensation. It does not indicate a discretionary sale or a change in sentiment towards the company.
Industry Context
This filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale to cover tax obligations related to equity compensation. It does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compliance Mechanism | Transaction executed under a Rule 10b5-1(c) plan, indicating a pre-arranged sale plan to comply with insider trading regulations. | 07/03/2025 | Enhances transparency and reduces the perception of opportunistic insider trading by establishing a pre-planned schedule for stock sales. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in executive confidence.
- Employees: No direct impact beyond the reporting executive.
Key Dates
| Date | Description |
|---|---|
| 07/03/2025 | Date of earliest transaction (disposition of shares) |
| 07/07/2025 | Signature date of the reporting person's attorney-in-fact |
Keywords
Integra LifeSciences, IART, Jeffrey Mosebrook, Form 4, insider transaction, stock disposition, tax withholding, executive compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.